| Literature DB >> 22071661 |
A Symons1, A L Budelsky, J E Towne.
Abstract
Th17 cells are abundant in multiple chronic inflammatory and autoimmune diseases. Clinical trials with antibodies to interleukin (IL)-17A, one of the Th17-cell signature cytokines, have recently reported therapeutic benefit in multiple patient populations; however, in Crohn's disease the role of Th17 cells and IL-17A appears to be more complicated. The development of different subsets of Th17 cells and their relative pathogenic activities with a focus on the gut environment will be discussed.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22071661 DOI: 10.1038/mi.2011.51
Source DB: PubMed Journal: Mucosal Immunol ISSN: 1933-0219 Impact factor: 7.313